Haematological malignancies are a large collection of heterogeneous blood cancers with huge variation in presentation, treatment and prognosis, ranging from acute leukaemias, high-grade lymphoma and aggressive multiple myeloma to more indolent neoplasms such as low-grade lymphomas and myelodysplastic syndromes (Ruiz et al., 2018). Intensive chemotherapy is used in the management of many haematological cancers, and this can result in severe and debilitating adverse events (Button, Bolton, et al., 2019a). Patients with